Two weeks after halting its trial of Actimmune after analyzing disappointing survival data, InterMune is dropping the axe on half of its staff in a bid to shave expenses by $40 million to $50 million next year. A total of 116 workers will lose their jobs in the restructuring. The company said it is switching focus to its late-stage trial of pirfenidone in idiopathic pulmonary fibrosis and on ITMN-191, an HCV protease inhibitor in early stage clinical development with Roche. Strong enrollment for its pirfenidone trial should allow it to get started several months early, company officials announced.
- here's the release [1] from InterMune
- read the report [2] from TheStreet.com
Related Articles:
InterMune terminates Actimmune trial. Report [3]
InterMune inks major collaboration with Roche. Report [4]
Roche gains hep C candidate with InterMune pact. Report [5]
Links:
[1] http://www.fiercebiotech.com/node/6097
[2] http://www.thestreet.com/_googlen/newsanalysis/biotech/10345420.html?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA
[3] http://www.fiercebiotech.com/story/intermune-terminates-actimmune-trial/2007-03-06
[4] http://www.fiercebiotech.com/story/intermune-inks-major-collaboration-with-roche/2006-11-02
[5] http://www.fiercebiotech.com/story/roche-gains-hep-c-candidate-with-intermune-pact/2006-10-17